RESUMEN
BACKGROUND: Hereby, we describe the first case of latent mastocytosis triggered by mRNA-based vaccine to prevent COVID-19 infection. CASE PRESENTATION: In a 42-year-old Arabian man affected by slight, undiagnosed mastocytosis, the second dose of the COVID-19 vaccine made more blatant his latent disease. The postvaccination diagnostic iter is illustrated and the potential reasons causing the onset of the cutaneous mastocytosis are discussed. CONCLUSION: In certain patients, clinicians should keep a longer follow-up of their patients, following the COVID-19 vaccination, not related to a few hours for the risk of immediate-type adverse events only.
RESUMEN
[This corrects the article DOI: 10.1016/j.radcr.2018.04.029.].
Asunto(s)
Deficiencia de alfa 1-Antitripsina , Deficiencia de alfa 1-Antitripsina/diagnóstico , Deficiencia de alfa 1-Antitripsina/genética , Deficiencia de alfa 1-Antitripsina/complicaciones , Humanos , Italia/epidemiología , Masculino , Femenino , Tamizaje Masivo , Persona de Mediana Edad , alfa 1-Antitripsina/genética , Anciano , AdultoRESUMEN
Biliary leakage is a challenging complication when managing the bile duct strictures. The etiology of benign strictures of the biliary tree may have different etiologies but iatrogenic is the most common, with relevant increase after introduction of laparoscopic procedures. Interventional radiologist plays a key role, both in diagnosis and treatment of biliary strictures and leakage. We report on a case of a 39-year-old woman affected by abdominal pain and jaundice after laparoscopic cholecystectomy; jaundice was caused by surgical clipping of the common bile duct. The combined management by surgeon and interventional radiologist, consisting of removal of surgical clip and percutaneous management of biliary leakage, successfully resolved the leakage with clinical success.